Connor, Clark & Lunn Investment Management (CC&L)
TRAX

Connor, Clark & Lunn Investment Management (CC&L)’s First Tracks Biotherapeutics TRAX Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio TRAX Stock Details TRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.32M Buy
+164,793
New +$3.08M 0.01% 853

Other funds holding TRAX

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s TRAX Position: Q2 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) opened a new position in First Tracks Biotherapeutics (TRAX) in Q2 2026: 164,793 shares worth $3.32M. The stake represents 0.01% of the portfolio and ranks #853 among its holdings.

150 funds tracked by Wall St. Rank hold TRAX as of Q2 2026.

  • Connor, Clark & Lunn Investment Management (CC&L) held 164,793 shares of First Tracks Biotherapeutics worth $3.32M as of Q2 2026.
  • First Tracks Biotherapeutics was a new Connor, Clark & Lunn Investment Management (CC&L) position in Q2 2026.
  • First Tracks Biotherapeutics made up 0.01% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q2 2026, its #853 holding.
  • 150 funds tracked by Wall St. Rank held First Tracks Biotherapeutics as of Q2 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2026, filed 13 Aug 2026.